Expression and Clinical Significance of lncRNA NCK1-AS1 in Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.02.007
- Author:
Chen CHENG
1
;
Zi-Jun XU
1
;
Pei-Hui XIA
1
;
Xiang-Mei WEN
1
;
Ji-Chun MA
1
;
Yu GU
2
;
Di YU
2
;
Jun QIAN
2
;
Jiang LIN
1
Author Information
1. Central Laboratory, the Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu Province, China.
2. Zhenjiang Clinical Research Center of Hematology,Zhenjiang 212002, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
lncRNA
- MeSH:
Humans;
Leukemia, Myeloid, Acute/genetics*;
RNA, Long Noncoding/genetics*;
Oncogene Proteins/genetics*;
Adaptor Proteins, Signal Transducing/genetics*;
Prognosis;
Male;
Female;
Middle Aged;
Adult;
Case-Control Studies;
Clinical Relevance
- From:
Journal of Experimental Hematology
2025;33(2):352-358
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect and analyze the expression and clinical significance of long non-coding RNA tyrosine kinase non-catalytic region adaptor protein 1-antisense RNA1 (NCK1-AS1) in patients with acute myeloid leukemia (AML).
METHODS:89 AML patients and 23 healthy controls were included from the People's Hospital Affiliated to Jiangsu University. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression levels of NCK1-AS1 and NCK1 in bone marrow samples. The relationship between the expression of NCK1-AS1 and the clinical characteristics of patients were analyzed, as well as the correlation between NCK1-AS1 and NCK1.
RESULTS:The expression level of NCK1-AS1 in all AML, non-M3 AML and cytogenetically normal AML (CN-AML) patients was significantly higher than that in the control group (P < 0.01, P < 0.05, P < 0.01, respectively). In non-M3 AML, patients with high NCK1-AS1 expression had a significantly lower hemoglobin level than those with low NCK1-AS1 expression (P =0.036), furthermore, NCK1-AS1 high patients had shorter overall survival than NCK1-AS1low patients (P =0.0378). Multivariate analysis showed that NCK1-AS1 expression was an independent adverse factor in patients with non-M3 AML ( HR =2.392, 95% CI :1.089-5.255, P =0.030). In addition, NCK1 expression was also significantly upregulated in all AML, non-M3 AML and CN-AML patients compared with controls (P < 0.01, P < 0.01, P < 0.001, respectively). There was a certain correlation between NCK1-AS1 and NCK1 expression (r =0.37, P =0.0058).
CONCLUSION:High expression of NCK1-AS1 in AML indicates poor prognosis of AML patients.
